Role of the blood-brain barrier in differential response to opioid peptides and morphine in mouse lines divergently bred for high and low swim stress-induced analgesia.
Over 20 years ago, the Sadowski group separated two mouse lines, one with high (HA) and the other with low (LA) sensitivity to swim stress-induced analgesia (SSIA). Recently, we proposed that increased leakage of the blood-brain barrier (BBB) in the HA line created the difference in the response to SSIA. To search for further evidence for this hypothesis, differences in the levels of the BBB proteins occludin and claudin-5 were analysed. In addition, we sought to evaluate practical differences in BBB permeability by examining the antinociceptive levels in HA and LA mouse lines after IV administration of peptides that have limited access to the CNS. Western blot was used to analyse the differences between occludin and claudin-5. To evaluate the functional differences between the BBB of HA and LA mice, the antinociception levels of endomorphin I, biphalin and AA2016 (peptides with limited BBB permeabilities) in the tail flick test were examined. The expression levels of occludin and claudin-5 in the HA mouse line were lower than in the LA and control mice. Central antinociception of the opioid peptides were significantly higher in the HA line than in the LA and control lines. Our data support the hypothesis that BBB leakage is responsible for the differences between the HA and LA mouse lines. Although SSIA confirmed BBB differences between both lines, it is not limited to the opioid system and could be a useful model for studying the role of the BBB in molecular communications between the periphery and CNS.
Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland, andrzej@lipkowski.org.
Anna
A
Kosson
Istvan
I
Krizbai
Anna
A
Lesniak
Malgorzata
M
Beresewicz
Mariusz
M
Sacharczuk
Piotr
P
Kosson
Peter
P
Nagyoszi
Imola
I
Wilhelm
Patrycja
P
Kleczkowska
Andrzej W
AW
Lipkowski
D000704:Analysis of Variance; D000777:Anesthetics / Q000494:pharmacology*; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects* / Q000502:physiology; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D062507:Claudin-5 / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D006930:Hyperalgesia / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains; D009020:Morphine / Q000494:pharmacology*; D062793:Occludin / Q000378:metabolism; D018847:Opioid Peptides / Q000494:pharmacology*; D010147:Pain Measurement / Q000187:drug effects; D017288:Pain Threshold / Q000187:drug effects; D010539:Permeability / Q000187:drug effects; D013045:Species Specificity; D013315:Stress, Psychological / Q000235:genetics / Q000473:pathology / Q000523:psychology; D013550:Swimming / Q000523:psychology*; D013997:Time Factors
D000777:Anesthetics; D062507:Claudin-5; D062793:Occludin; D018847:Opioid Peptides; D009020:Morphine